Oncolytics Biotech Announces REO 033 Colorectal Study Update

What Happened
On September 28, 2026, Oncolytics Biotech Inc. (ONCY) filed a Form 8-K (Item 8.01) to announce certain updates and reported progress related to its REO 033 colorectal cancer clinical study. The company also issued a press release the same day summarizing the updates.

Key Details

• Filing date: September 28, 2026 (Form 8-K, Item 8.01 — Other Events).
• Press release attached as Exhibit 99.1, dated September 28, 2026.
• Interactive XBRL cover page included as Exhibit 104.
• Form 8-K was signed by Kirk Look, Chief Financial Officer, on behalf of the company.

Why It Matters
Clinical-trial updates are material for biotech investors because they can affect timelines, regulatory views and future development plans. This 8-K confirms Oncolytics is communicating progress on the REO 033 colorectal study; investors should read the linked press release for the specific clinical details and monitor future SEC filings or company announcements for data, milestones, or changes to the development plan.